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ABSTRACT         
Background: Eosinophil cationic protein (ECP) is a cytotoxic agent secreted 
by activated eosinophils during allergic and inflammatory processes. The aim of the 
study was to determine ECP level, absolute and relative eosinophil count and IgE 
antibodies in children with atopic dermatitis (AD), compare them to the levels in non-
atopic children, and to assess correlation of these laboratory parameters with clinical 
severity of AD. Methods: The prospective study encompassed 70 children. There 
were 49 children with AD aged 3 to 36 months and the control group comprised 21 
children, with negative personal and family history for atopic diseases. Detailed 
history, serum ECP levels (UniCAP FEIA), relative and absolute eosinophil counts 
and total serum IgE antibodies were determined in both groups. In AD children the 
skin involvement was measured by SCORAD index. Results: The calculated 
SCORAD index was between 16 and 83. IgE antibodies, relative and absolute 
eosinophil counts showed a much wider range of values and a statistically higher 
median (p<0.001) in AD patients compared to the control group. These laboratory 
parameters did not correlate with the severity of AD. The serum ECP median level, in 
children with AD, was 16.2 µg/L (range 3.01-65.30) compared to 5.92 µg/L (range 
2.76-21.90) in the control group. The correlation of total SCORAD index and serum 
ECP levels was negative, weak (r=-0.065) and statistically not significant (p>0.05). 
The same was found for the correlation of serum ECP and intensity of skin changes 
(r=-0.095) and serum ECP and subjective symptoms (r=-0.045). The correlation was 
positive, but weak and statistically not significant for serum ECP and extent of skin 
lesions (r=0.079, p>0.05). Conclusion: Elevated levels of ECP, relative and absolute 
eosinophil counts, as well as IgE antibodies were determined in the patients with AD. 
Since these laboratory findings did not correlate with the severity of AD, they can be 
considered only as additional methods in the evaluation of patients with AD.   
  
 
3 
INTRODUCTION 
Atopic dermatitis (AD) is a chronic, recurring, allergic inflammatory skin 
disease caused by genetic predisposition (atopic constitution) and characterized by 
typical clinical presentation. This disorder, primarily occurring in infants and 
children, is the most common disease seen in pediatric dermatology practice with the 
prevalence reaching 15% in this age group (1,2). The development of AD is 
dependent on multiple genes but environmental factors influence the expression of the 
disease (3,4). 
The pathogenesis of the disease is still unclear. In the past, considerable debate 
was led whether AD is primarily an allergen-induced disease or simply an 
inflammatory skin disorder (5). Recent data strongly support that AD is an allergic 
disorder associated with asthma and allergic rhinitis (6).  
Serum levels of IgE antibodies are elevated in 80-85% patients with AD. 
Disturbance of skin function, reflected by increased skin sensitivity, dryness and 
infection, appear to be more important than allergy in inducement and maintain of 
skin inflammation in some patients (6). 
Eosinophilia is a common finding in patients with atopy. The investigations in 
the last few decades have clearly pointed out that eosinophils, owing to their 
functional capabilities and toxic proteins, represent active proinflammatory cells that 
cause different symptoms in allergic diseases (7-9). Eosinophils are activated through 
various cytokines and inflammatory mediators, which lead to invasion of eosinophils 
to the site of inflammation (10,11). At the site of inflammation eosinophils secrete 
leukotriens, prostaglandins, bradikinin, various cytokines, enzymes as well as 
different toxic proteins from their granules (12). Eosinophil cationic protein (ECP), 
secreted by eosinophils, is a cytotoxic agent that plays an important role in the 
propagation of allergic inflammation and has an immunomodulatory capacity (13).  
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There are various means of eosinophil monitoring and determination of their 
involvement in diseases: eosinophil count in blood and tissue, identification of 
activated eosinophils in blood (hypodense eosinophils), identification of activated 
eosinophils in tissue with monoclonal antibody staining-EG2 antibody (14) and 
eosinophil cationic protein (ECP) in different body fluids. 
Elevated ECP levels have been measured in serum, bronchoalveolar and nasal 
secretions in patients with allergic diseases such as bronchial asthma and allergic 
rhinitis (15,16).  Significantly elevated levels of ECP have been found in patients with 
AD (17-27). It seems likely that elevated levels reflect the state of eosinophil 
activation in the skin so ECP may represent a laboratory parameter for identification 
of pathologic inflammatory processes and degree of eosinophil involvement in the 
skin of AD patients.  
The aim of this study was to determine levels of ECP, absolute and relative 
eosinophil count and IgE antibodies in children with AD, compare them to the levels 
in non-atopic children and to assess correlation of these laboratory data with clinical 
severity of AD.  
 
MATERIALS AND METHODS 
Patients 
Seventy children divided in two groups were included in the study. The first 
group consisted of 49 children, aged 3-36 months, with the diagnosis of AD according 
to the criteria established by Hanifin and Rajka (28). There were 17 girls and 32 boys. 
The patients were recruited from the Outpatient Clinic or were hospitalized at the 
Department of Dermatolovenerology, Zagreb University Hospital Center, Croatia, 
from February to October 2000.  The children were otherwise healthy, had no 
symptoms that could be related to any other allergic illness, and their only current 
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treatment were skin moisturizers. They were not previously treated by ultraviolet 
therapy, systemic corticosteroids or immunosuppressive medications.  
The control group comprised 21 children, of the same age, with negative 
personal and family history for atopic diseases. They were selected, between patients 
who were monitored and considered healthy after treatment of urinary or respiratory 
infection at the Outpatient Pediatric Clinic of Zagreb University Hospital Center, 
Croatia.  
Methods 
Detailed history, relative and absolute eosinophil counts, total serum IgE 
antibodies and serum ECP levels were determined in both groups. Serum ECP value 
was determined by UniCAP-ECP Fluoroimmunoassay-Pharmacia (29). Blood 
samples for serum ECP were collected, handled and prepared according to the 
instructions of the manufacturer (29).  The blood was collected by venipuncture using 
Becton Dickinson 2,5 ml Vacutainer hemogard SST® tubes for serum separation. 
After collection the tubes were gently inverted 5 times then left for 90 minutes at 
room temperature (20-240C) for clotting. Centrifugation at 1300xg for 10 minutes was 
performed, the serum was transferred to a new tube and stored at –200C until 
analysed. The absolute number of eosinophils was calculated from the total number of 
leukocytes and percentage of eosinophils determined by counting of 400 leukocytes. 
Total IgE antibody values were determined by UniCAP 100 method-Pharmacia CAP 
System IgE FEIA (30).   
In AD children, the extent of the disease and severity of symptoms was 
calculated by SCORAD index (31).  
Statistics 
Data analysis was carried out by release 6.12, the SAS computer program. The 
Mann-Whitney U test was used to determine differences between the study and 
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control group. Relationship between different parameters was determined by 
Spearman coefficient correlation. The results of statistical analysis with p<0.05 were 
considered statistically significant.  
  
Results 
Out of 49 children with AD, 26 (53.1%) had a positive family history for 
atopy. The mean age of AD onset was 3.0 months.  
SCORAD index values were between 16 and 83. The majority of our patients 
(35 patients) had SCORAD index between 31 and 65 (Figure 1) therefore the clinical 
picture was moderately severe.  
IgE antibody values ranged between 2.0 and 124.0 kIJ/L in healthy children, 
and between 2.6 and 5,000.0 kIJ/L in patients with AD. The median value of IgE in 
AD patients was 98.3 kIJ/L, which was significantly higher (p<0.001) compared to 
the median of healthy controls (10.0 kIJ/L).  
Healthy controls had values of relative eosinophil numbers from 0 to 11% 
compared to 0 to 34% in AD children. Median for this laboratory parameter was 2% 
in healthy children and 7 % in children with AD. 
Absolute eosinophil count in AD children showed values from 0.01 to 3.69 x 
109/L compared to 0.02 to 1.27 x 109/L. The median values were 0.70 (AD children) 
and 0.09 (healthy controls).  
The mean value, of serum ECP in AD patients, was 16.20 µg/L and 
significantly higher (p<0.001) compared to 5.92 µg/L in healthy controls. As found 
for IgE and eosinophil numbers the values varied greatly in AD patients (3.01-65.30 
µg/L) compared to healthy controls (2.76 –21.90 µg/L).  
Correlation between clinical (SCORAD) and laboratory parameters (ECP, 
eosinophils, IgE) in children with AD are shown in Tables 1-3.  
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The correlation of serum ECP levels and total SCORAD index (Table 1) was 
negative, weak (r=-0.065) and statistically not significant. The same was found for the 
correlation of serum ECP and intensity of skin lesions (r=-0.095) as well as the 
correlation between serum ECP and subjective symptoms (r=-0.045). The correlation 
between ECP and extent of skin lesions was positive, weak (r=0.079) and statistically 
not significant.  
The relationship of serum ECP with relative and absolute eosinophil counts 
(Table 2) showed medium strong, positive (r=0.533; r=0.459) and statistically highly 
significant correlation. The correlation between ECP and IgE (Table 2) antibodies was 
positive, weak (r=0.038) and statistically not significant.  
Negative, weak and statistically nonsignificant correlation was determined 
between SCORAD index and relative as well as absolute eosinophil counts (r=-0.059; 
r=-0.104). The correlation of SCORAD index and IgE antibodies was positive, weak 
(r=0.150) and statistically nonsignificant (Table 3). 
 
DISCUSSION  
Atopic dermatitis is a chronic-relapsing disease characterized by exacerbations 
for which the cause is usually not evident. For clinical evaluation of momentary 
disease activity SCORAD index is widely used because of its simplicity and 
reliability. It combines numerous symptoms of the disease. The intensity of skin 
symptoms accounts for 60% of the total score while subjective symptoms and extent 
of the disease account for 20% each (31).   
Some laboratory parameters are frequently elevated in patients with AD so 
their correlation with SCORAD index can be assumed.  
Although our results confirm data from the literature according to which 
patients with AD have elevated levels of eosinophils (7-9), IgE antibodies (6) and 
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ECP (17-27), the correlations between any of these laboratory parameters and 
SCORAD index were not determined.  
Comparison of our correlation results with those from other authors is hard 
because of the differences in patients’ age and/or severity of their disease. Some 
studies, in which severity of the disease was measured by the SCORAD method, 
showed positive and statistically significant correlation (25,27), others (26) gained 
results as we did - negative, weak and statistically not significant correlation. Positive, 
medium strong and statistically significant correlations were determined in studies 
that used COSTA (20), SIS (21) and a modified method (24) for clinical evaluation of 
the disease. 
Lack of correlation between ECP and SCORAD can be explained by several 
reasons. SCORAD index is widely used for clinical evaluation of disease activity in 
patients with AD because of its simplicity and reliability. It reflects momentary 
disease state and does not give information about the severity of the disease in 
general. Subjective symptoms such as pruritus and sleep loss that account for 20% of 
the total SCORAD index are hard to evaluate in children. 
The nature of data and their statistical interpretation should also be taken with 
certain caution. In our patients the SCORAD index ranged from 16 to 83. The large 
majority (45 patients) had moderate to severe clinical picture with SCORAD index 
over 30. Our results are probably influenced by low percentage of patients with high 
and low SCORAD index values. Comparing a quantitative parameter like ECP with a 
semi quantitative one, like SCORAD index, straight correlation is rarely observed.  
The serum level of ECP is considered to express “activation” status of peripheral 
blood eosinophils but mechanisms of the release, however, are still not completely 
understood. Results of some investigations (33) conclude that the serum level of ECP 
represents the level found in vivo, plus additional protein released in vitro from 
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peripheral blood eosinophils during the coagulation period. Other investigators 
concluded that serum ECP level measurements are unrelated to the coagulation 
process (34).  
It is important that recommendations for blood sample collection, handling and 
preparation are strictly followed. In our study recommendations of the manufacturer 
were strictly followed and the blood was left for coagulation for 90 minutes at room 
temperature before centrifugation.  
ECP is generally regarded as protein specific for eosinophils. It has been 
documented that ECP, or protein immunologically cross-reactive with ECP, is present 
in neutrophilic leukocytes as well (35).  Therefore, increased ECP serum levels can 
partly be the result of neutrophil degranulation, and influenced by skin infection often 
observed in patients with AD.  
Clinical scoring of disease activity in patients with AD still remains the most 
effective and relevant method for determination of the severity and course of the 
disease as well as response to various treatments. Based on our results we can 
conclude that eosinophils and proteins from their granules, such as eosinophil cationic 
protein, have a role in the pathogenesis of AD. Therefore these laboratory data can 
give additional information on pathogenesis and inflammatory mechanisms involved 
(36). More investigations of correlation between SCORAD index and ECP are 
needed. They should include a greater number of patients with mild and severe 
clinical picture. If correlation exists the determination of ECP level will be justified as 
an additional, laboratory method in the evaluation, follow up and treatment of patients 
with AD. 
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Table 1. Correlation coefficients for SCORAD index parameters and serum ECP level 
in children with AD 
                                                                                        E C P level 
SCORAD index parameter                                  --------------------------------- 
                                                                              r                                 p 
Total SCORAD index    -0.065                         0.655 
Extent of skin lesions     0.079                          0.586                                          
Intensity of skin lesions   -0.095                          0.515   
Subjective symptoms    -0.045                          0.758 
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Table 2. Correlation coefficients for laboratory parameters and serum ECP level in 
children with AD 
                                                                                   E C P level 
Laboratory parameter                                         ----------------------------- 
                                                                            r                                 p 
Eosinophils (%)    0.533                         0.000 
Absolute eosinophil count   0.459                         0.001                                          
IgE      0.038                         0.804  
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Table 3. Correlation coefficients for laboratory parameters and total SCORAD index 
                                                  in children with AD  
                                                                                Total SCORAD index 
Laboratory parameter                                         --------------------------------- 
                                                                                r                               p 
Eosinophils (%)    -0.059                          0.684 
Absolute eosinophil count   -0.104                          0.475                                          
IgE       0.150                          0.330  
  
 
 
 
 
 
 
 
